Welcome to our dedicated page for REVIVA PHARMACEUTICALS HOLDINGS SEC filings (Ticker: RVPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REVIVA PHARMACEUTICALS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REVIVA PHARMACEUTICALS HOLDINGS's regulatory disclosures and financial reporting.
Barclays PLC filed an amended Schedule 13G reporting its beneficial ownership in Reviva Pharmaceuticals Holdings common stock. Barclays reports beneficial ownership of 20 shares, representing 0.00% of the class as of June 30, 2026. Barclays has sole voting power and sole dispositive power over all 20 shares, with no shared voting or dispositive power. The filing confirms that Barclays’ holdings are classified as ownership of 5 percent or less of the class.
Reviva Pharmaceuticals Holdings, Inc. reported unaudited results for the quarter ended June 30, 2026. Cash and cash equivalents were $19.9 million, up from $14.4 million at December 31, 2025, and working capital surplus was $15.2 million. Total assets were $21.1 million.
The company generated no product revenue and recorded a net loss of $2.4 million for the quarter and $5.6 million for the first half of 2026, narrower than the prior-year periods, driven by sharply lower research and development expenses (down to $1.4 million from $3.7 million in the quarter) as its RECOVER-1 open-label extension study wound down, and reduced general and administrative costs.
Reviva raised capital through a March 2026 public offering, which delivered net proceeds of about $8.9 million, and an at-the-market program that added approximately $2.5 million in the first half, and it has significant warrant overhang. Management believes existing cash can fund operations into July 2027, yet explicitly states that cash on hand is not sufficient for 12 months from issuance and discloses substantial doubt about its ability to continue as a going concern without additional financing. During the period, the company completed a 1-for-20 reverse stock split and its common stock was delisted from Nasdaq and is now quoted on the OTCQB Venture Market.
Reviva Pharmaceuticals Holdings, Inc. reported second quarter 2026 results and outlined key milestones for its lead drug candidate brilaroxazine. A U.S. composition of matter patent application for a new form of brilaroxazine is seeking accelerated review, which the company believes could extend patent life and commercial exclusivity through 2046. FDA feedback on use of the new formulation in the RECOVER-2 registrational Phase 3 schizophrenia trial and in a planned New Drug Application is expected in the fourth quarter of 2026, with a bioequivalence study planned for the same period and RECOVER-2 patient enrollment targeted for the first half of 2027, subject to additional financing.
Cash and cash equivalents were $19.9 million as of June 30, 2026, up from $14.4 million at December 31, 2025, with total assets of $21.1 million and total liabilities of $5.9 million. For the quarter, operating expenses fell to $2.6 million from $6.1 million a year earlier, and net loss narrowed to $2.45 million (or $0.19 per share) from $6.05 million (or $2.40 per share). Stockholders’ equity increased to $15.2 million, while accumulated deficit reached $189.8 million. The company’s common stock now trades on the OTCQB Venture Market under the symbol RVPH.
Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 1,072,690 shares of Reviva Pharmaceuticals Holdings, Inc. common stock on this Amendment No. 1 to Schedule 13G. This position represents 8.2% of the outstanding class.
The reporting persons have shared voting and dispositive power over all 1,072,690 shares and no sole voting or dispositive power. The shares are held by entities subject to voting control and investment discretion of Millennium Management LLC and related managers, and the filing states that this structure should not, by itself, be construed as an admission of beneficial ownership. The parties also enter into a Joint Filing Agreement dated July 31, 2026.
UBS Group AG, together with its wholly owned subsidiaries UBS Financial Services Inc. and UBS Securities LLC, reports that it no longer beneficially owns any shares of Reviva Pharmaceuticals Holdings, Inc. common stock, par value $0.0001 per share.
As of 06/30/2026, UBS Group discloses 0 shares beneficially owned, representing 0% of the class. It reports no sole or shared voting power and no sole or shared dispositive power over Reviva common stock, and indicates that it now holds 5 percent or less of the class.
Reviva Pharmaceuticals Holdings, Inc. notified that its Common Stock will be removed from listing and/or registration on the Nasdaq Stock Market LLC under Form 25; Nasdaq certifies it has complied with 17 CFR 240.12d2-2 and the issuer has complied with Exchange rules governing voluntary withdrawal.
Reviva Pharmaceuticals Holdings, Inc. is the subject of a Schedule 13G/A reporting that CVI Investments, Inc. and Heights Capital Management, Inc. collectively hold 672,811 shares of common stock, representing 4.9% of the class. The filing states these shares "consist of Shares issuable upon the exercise of warrants" and that the warrants are restricted so exercises cannot cause ownership to exceed 4.99%. The company reported 12,810,377 Shares outstanding as of March 27, 2026. The filing is signed on 05/13/2026.
Reviva Pharmaceuticals Holdings files a Schedule 13G reporting Barclays PLC beneficial ownership of 763,579 shares. The filing states Barclays holds 763,579 shares of Reviva common stock (CUSIP 76152G209), representing 5.96% of the class as of 03/31/2026. Barclays is shown with sole voting and sole dispositive power over the same 763,579 shares. The filing names Barclays Bank PLC as the relevant subsidiary and is signed by a director on 05/14/2026.
Reviva Pharmaceuticals Holdings, Inc. reported a narrower net loss of about $3.2 million for the three months ended March 31, 2026, compared with $6.4 million a year earlier, mainly due to sharply lower research and development spending. R&D expenses fell to roughly $1.4 million from $4.1 million, and general and administrative costs declined to about $1.8 million from $2.4 million.
Cash and cash equivalents increased to $22.2 million as of March 31, 2026, driven by financing activities, including a March 2026 public offering with $10.0 million in gross proceeds and an at-the-market equity program that raised about $2.5 million. Working capital surplus rose to approximately $17.4 million, and total stockholders’ equity more than doubled to about $17.4 million.
The company remains a clinical-stage biotech with no product revenue and an accumulated deficit of roughly $187.3 million. Management states that existing cash is expected to fund operations into early 2027 but explicitly concludes there is substantial doubt about Reviva’s ability to continue as a going concern without additional capital. During the quarter, Reviva also effected a 1‑for‑20 reverse stock split and later received notice that its shares will be delisted from Nasdaq and quoted on the OTCQB Venture Market under “RVPH.”
Reviva Pharmaceuticals Holdings, Inc. reported a first quarter 2026 net loss of $3,195,987, about half the $6,432,840 loss a year earlier, as operating expenses fell to $3,271,952 from $6,538,167. Net loss per share narrowed to $0.46 from $2.61, reflecting both lower spending and higher share count.
Cash and cash equivalents rose to $22,190,231 as of March 31, 2026, up from $14,438,792 at year-end, driving total stockholders’ equity to $17,440,481. The company continues to invest in its late-stage CNS pipeline, led by brilaroxazine.
Reviva filed a composition of matter provisional patent application for a new form of brilaroxazine intended to extend commercial exclusivity through 2046. It expects FDA feedback on using this new form in the RECOVER-2 registrational Phase 3 schizophrenia trial and future NDA in mid-2026, with patient enrollment in RECOVER-2 targeted to begin in Q3 2026. Trading of Reviva’s common stock on Nasdaq will be suspended on May 14, 2026, and the shares will be quoted on the OTCQB Venture Market under the symbol RVPH.